SUBSCRIBE
SUBSCRIBE
News   Policy

ProStrakan Group Says FDA Seeks More Data on Pain Ointment

April 1, 2010 | 
1 min read
Reuters -- Scottish speciality pharmaceutical firm ProStrakan Group Plc (PSK.L) said U.S. health regulators sought further data on Rectogesic, an ointment for pain associated with chronic anal fissures, delaying approval for the drug.
Regulatory
MORE ON THIS TOPIC
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
 · 
2 min read
 · 
Jef Akst
Illustration showing businessman trying to create his own road
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
 · 
3 min read
 · 
Annalee Armstrong
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
 · 
1 min read
 · 
Jef Akst
Creative concept of leadership and innovation with a glowing blue light bulb leading paper planes. Symbol of advanced technology, AI-driven strategy, and visionary direction in a digital future.
Regulatory
FDA opens Operation TrialBlazer for applications, hoping to reshore early trials
September 15, 2026
 · 
1 min read
 · 
Heather McKenzie